K. Fink et al., Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices, BR J PHARM, 130(4), 2000, pp. 900-906
Cytosolic calcium ion concentrations ([Ca2+](i)) were measured in rat neoco
rtical synaptosomes using fura-2, and depolarization of synaptosomal membra
nes was induced by K+ (30 mM). The release of the endogenous excitatory. am
ino acids glutamate and aspartate was evoked by K+ (50 mM) and determined b
y HPLC. The release of [H-3]-noradernaline from rat neocortical synaptosome
s or slices was evoked by K+ (15 and 25 mM) and measured by liquid scintill
ation counting.
2 Gabapentin produced a concentration-dependent inhibition of the K+-induce
d[Ca2+](i) increase in synaptosomes (IC50 = 14 mu M; maximal inhibition by
36%). The inhibitory effect of gabapentin was abolished in the presence of
the P/Q-type Ca2+ channel blocker omega-agatoxin IVA, but not by the N-type
Ca2+ channel antagonist omega-conotoxin GVIA.
3 Gabapentin (100 mu M) decreased the K+-evoked release of endogenous aspar
tate and glutamate in neocortical slices by 16 and 18% respectively.
4 Gabapentin reduced the K+-evoked [H-3]-noradrenaline release in neocortic
al slices (IC50 = 48 mu M; maximal inhibition of 46%) but not from synaptos
omes.
5 In the presence of the AMPA receptor antagonists 6-cyano-7-nitroquinoxali
ne-2,3-dione (CNQX) and 2.3-dioxo-6-nitro-1,2,3,4-tetrahydro[f]quinoxaline-
7-sulphonamide (NBQX), gabapentin did not reduce [H-3]-noradrenaline releas
e. Gabapentin did, however, cause inhibition in the presence of the NMDA re
ceptor antagonist DL-(E)-2-amino-4-methyl-5-phosphono-3-pentanoic acid (CGP
37849).
6 Gabapentin is concluded to reduce the depolarizatian-induced [Ca2+](i) in
crease in excitatory amino acid nerve terminals by inhibiting P/Q-type Ca2 channels; this decreased Ca2+ influx subsequently attenuates K+-evoked exc
itatory amino acid release. The latter effect leads to a reduced activation
of AMPA receptors which contribute to K+-evoked noradrenaline release from
noradrenergic varicosities, resulting in an indirect inhibition of noradre
naline release.